{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T21:40:33Z","timestamp":1767908433049,"version":"3.49.0"},"reference-count":12,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,3,3]],"date-time":"2025-03-03T00:00:00Z","timestamp":1740960000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Immune checkpoint inhibitors are increasingly being utilized for the treatment of advanced neoplastic disease, and Sintilimab as a selective anti\u2013PD-1 antibody that inhibits interactions between PD-1 and its ligand, is a typical representative of them. Among all the adverse effects(AEs) of sintilimab, skin AEs had affected many people. Though exceedingly rare, eruptive keratoacanthomas-like lesion have been associated with the use of immune checkpoint inhibitors before. Here, we report a case of numerous eruptive keratoacanthoma-like lesions arising in a patient 2 weeks after initiation of sintilimab for rectal adenocarcinoma with liver metastasis. Although eruptive keratoacanthoma-like lesions secondary to sintilimab are exceptionally rarely reported, physicians should be aware of this cutaneous adverse effect as its use becomes more widespread.<\/jats:p>","DOI":"10.3389\/fimmu.2025.1535220","type":"journal-article","created":{"date-parts":[[2025,3,3]],"date-time":"2025-03-03T07:04:50Z","timestamp":1740985490000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":4,"title":["Case Report: Multiple cutaneous keratoacanthoma-like lesions in a colorectal cancer patient treated with sintilimab"],"prefix":"10.3389","volume":"16","author":[{"given":"Shiyi","family":"Li","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xianhui","family":"Ye","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaofen","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2025,3,3]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-021-01489-2","article-title":"Combination strategies with PD-1\/PD-L1 blockade: current advances and future directions","volume":"21","author":"Yi","year":"2022","journal-title":"Mol Cancer."},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2020.07.014","article-title":"Efficacy and Safety of Sintilimab Plus Pemetrexed and Platinum as First-Line Treatment for Locally Advanced or Metastatic Nonsquamous NSCLC: a Randomized, Double-Blind, Phase 3 Study (Oncology pRogram by InnovENT anti-PD-1-11)","volume":"15","author":"Yang","year":"2020","journal-title":"J Thorac Oncol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.2340\/00015555-3301","article-title":"Multiple keratoacanthoma-like lesions in a patient treated with pembrolizumab","volume":"99","author":"Fradet","year":"2019","journal-title":"Acta Dermato-Venereologica."},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1007\/s00403-022-02468-3","article-title":"To treat or not to treat: PD-L1 inhibitor-induced keratoacanthoma and squamous cell carcinoma","volume":"315","author":"Poole","year":"2023","journal-title":"Arch Dermatol Res"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2015.11.033","article-title":"Keratoacanthoma (KA): An update and review","volume":"74","author":"Kwiek","year":"2016","journal-title":"J Am Acad Dermatol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1038\/s41422-020-0343-4","article-title":"Immune checkpoint signaling and cancer immunotherapy","volume":"30","author":"He","year":"2020","journal-title":"Cell Res"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-019-1066-z","article-title":"Sintilimab: first global approval","volume":"79","author":"Hoy","year":"2019","journal-title":"Drugs."},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.3390\/curroncol29040234","article-title":"Cutaneous adverse events associated with immune checkpoint inhibitors: A review article","volume":"29","author":"Chen","year":"2022","journal-title":"Curr Oncol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.3390\/curroncol30070498","article-title":"Molecular mechanisms of cutaneous immune-related adverse events (irAEs) induced by immune checkpoint inhibitors","volume":"30","author":"Teng","year":"2023","journal-title":"Curr Oncol"},{"key":"B10","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1097\/CJI.0000000000000498","article-title":"Multiple eruptive keratoacanthomas secondary to nivolumab immunotherapy","volume":"47","author":"Olsen","year":"2024","journal-title":"J Immunother"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.43402","article-title":"Pembrolizumab-induced eruptive keratoacanthomas and lichen planus in a lung cancer patient","volume":"15","author":"Tembunde","year":"2023","journal-title":"Cureus."},{"key":"B12","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1001\/jamadermatol.2020.0176","article-title":"Treatment of PD-1\/PD-L1 inhibitor-induced dermatitis resolves concomitant eruptive keratoacanthomas","volume":"156","author":"Crow","year":"2020","journal-title":"JAMA Dermatol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1535220\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,3]],"date-time":"2025-03-03T07:04:53Z","timestamp":1740985493000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1535220\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,3]]},"references-count":12,"alternative-id":["10.3389\/fimmu.2025.1535220"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2025.1535220","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,3]]},"article-number":"1535220"}}